Cefotiam

Source: Wikipedia, the free encyclopedia.
Cefotiam
Clinical data
Trade namesPansporin
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Intravenous, intramuscular
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability60% (intramuscular)
Protein binding40%
MetabolismNil
Elimination half-lifeApproximately 1 hour
ExcretionRenal
Identifiers
  • (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)acetyl]
    amino}-3-{[1-(2-dimethylaminoethyl)tetrazol-5-yl]
    sulfanylmethyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]
    oct-2-ene-2-carboxylic acid
JSmol)
  • CN(C)CCN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
  • InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1 checkY
  • Key:QYQDKDWGWDOFFU-IUODEOHRSA-N checkY
  (verify)

Cefotiam is a

Gram-negative bacteria. As a beta-lactam, its bactericidal activity results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins
.

It was patented in 1973 and approved for medical use in 1981.[1]

Medical uses

This drug is indicated for prophylaxis for surgical infection, postoperative infections, bacterial

cystitis, urethritis, and infections caused by susceptible organisms. It does not have activity against Pseudomonas aeruginosa.[citation needed
]

Dosage

For adults, the dose is up to 6 grams daily by intravenous or intramuscular route in divided doses according to severity of infection. In patients with

renal impairment a dose reduction may be needed.[citation needed
]

Spectrum of bacterial susceptibility

Cefotiam has a broad spectrum of activity and has been used to treat infections caused by a number of enteric bacteria and bacteria responsible for causing skin infections. The following represents MIC susceptibility data for a few medically significant bacteria.

  • Bacteroides fragilis: - 16 - >128 μg/ml
  • Clostridium difficile: >128 μg/ml
  • Staphylococcus aureus: 0.25 - 32 μg/ml

[2]

Adverse effects

Side effects include nausea and vomiting, diarrhoea, hypersensitivity reactions,

pseudomembranous colitis, and superinfection with prolonged use.[citation needed
]

Mechanism of action

Cefotiam inhibits final cross-linking stage of

E. coli, Klebsiella, Salmonella and indole-positive Proteus species.[citation needed
]

In clinical use, high concentrations of cefotiam are observed in several tissues (kidney, heart, ear, prostate, and genital tract), as well as in fluids and secretions (bile, ascitic fluid).[citation needed]

References

  1. ISBN 978-3-527-60749-5
    .
  2. ^ "Cefotiam hydrochloride" (PDF). Susceptibilty and Resistance Data. TOKU-E. 24 February 2014. Archived from the original (PDF) on 2016-03-04. Retrieved 2014-02-06.

Further reading

Retrieved from "https://en.wikipedia.org/w/index.php?title=Cefotiam&oldid=1180738266"